Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

NCT04200443 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04200443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04200443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 14, 2020
Completion date
September 10, 2026
Enrollment
96 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic leiomyosarcoma, metastatic soft tissue sarcoma, stage iii uterine corpus leiomyosarcoma ajcc v8, stage iiia uterine corpus leiomyosarcoma ajcc v8, stage iiib uterine corpus leiomyosarcoma ajcc v8, stage iiic uterine corpus leiomyosarcoma ajcc v8, stage iv uterine corpus leiomyosarcoma ajcc v8, stage iva uterine corpus leiomyosarcoma ajcc v8, stage ivb uterine corpus leiomyosarcoma ajcc v8, unresectable leiomyosarcoma, unresectable soft tissue sarcoma